Filgotinib for moderately to severely active ulcerative colitis

Alessandro Mannucci, Ferdinando D’Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese

Open source

DOI
10.1080/17474124.2022.2138857
Published
2022-10-03
Container
Expert Review of Gastroenterology & Hepatology
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/17474124.2022.2138857,
  title = {Filgotinib for moderately to severely active ulcerative colitis},
  author = {Alessandro Mannucci and Ferdinando D’Amico and Ahmad El Saadi and Laurent Peyrin-Biroulet and Silvio Danese},
  year = {2022},
  journal = {Expert Review of Gastroenterology \& Hepatology},
  doi = {10.1080/17474124.2022.2138857},
  url = {https://doi.org/10.1080/17474124.2022.2138857}
}

RIS

TY  - JOUR
TI  - Filgotinib for moderately to severely active ulcerative colitis
AU  - Alessandro Mannucci
AU  - Ferdinando D’Amico
AU  - Ahmad El Saadi
AU  - Laurent Peyrin-Biroulet
AU  - Silvio Danese
PY  - 2022
JO  - Expert Review of Gastroenterology & Hepatology
DO  - 10.1080/17474124.2022.2138857
UR  - https://doi.org/10.1080/17474124.2022.2138857
ER  - 

APA

Mannucci, A., D’Amico, F., Saadi, A. E., Peyrin-Biroulet, L., & Danese, S. (2022). Filgotinib for moderately to severely active ulcerative colitis. Expert Review of Gastroenterology & Hepatology. https://doi.org/10.1080/17474124.2022.2138857

Source records